KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Jian Ming Xu, Xiao Jing Liu, Fei Jiao Ge, Li Lin, Yan Wang, Manish R. Sharma, Ze Yuan Liu, Stefania Tommasi, Angelo Paradiso

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.

METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.

RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p 

CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

Original languageEnglish
Pages (from-to)104
Number of pages1
JournalJournal of Experimental and Clinical Cancer Research
Volume33
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this